Wednesday, November 25, 2009, 8:30am EST - Canadian Markets open in 1 hour.
To create a watchlist or portfolio of shares, Sign-in or Register

IR Biosciences Holdings Inc. (IRBS.OB)

 On Nov 24: 0.20 USD   0.00 (0.00%)  
MORE ON IRBS.OB
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
IR BIOSCIENCES HLDGS (OTC BB:IRBS.OB) Delayed quote dataEdit
Last Trade: 0.20 USD
Trade Time: Nov 24
Change: 0.00 (0.00%)
Prev Close: 0.20
Open: N/A
Bid: 0.15 x 5000
Ask: 0.20 x 5000
1y Target Est: 2.00
Day's Range: N/A - N/A
52wk Range: 0.02 - 1.18
Volume: 0
Avg Vol (3m): 17,996.8
Market Cap: 2.65M
P/E (ttm): N/A
EPS (ttm): -0.62
Div & Yield: N/A (N/A%)
IR Biosciences Holdings Inc. (IRBS.OB)
1d  5d  3m  6m  1y  2y  5y  max 
 Add IRBS.OB to Portfolio   Download Data

HEADLINES
• IR BIOSCIENCES HOLDINGS INC Financials
EDGAR Online Financials (Sat, Nov 21)
• IR BIOSCIENCES HOLDINGS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Mon, Nov 16)
• ImmuneRegen BioSciences(R) Reports Positive Results of Homspera(R) in Treating Highly Pathogenic Influenza
Marketwire (Tue, Nov 10)
• ImmuneRegen BioSciences(R) to Further Homspera(R) Research in Study Funded by U.S. Government
Marketwire (Thu, Oct 22)
• ImmuneRegen BioSciences(R) Initiates Homspera(R) Studies Against Global Influenza Threat
Marketwire (Mon, Oct 12)
• ImmuneRegen BioSciences(R) Announces Strategic Partnership With Azopharma Product Development Group, Inc.
Marketwire (Wed, Sep 23)
• ImmuneRegen BioSciences(R) Announces Partnership With Bachem, Inc., for Manufacturing of Homspera(R)
Marketwire (Tue, Sep 22)
• IR BioScience Holdings Inc. CFO Interview: John N. Fermanis
Wall Street Transcript (Tue, Sep 15)
• Arrowhead Research Corp. CEO and President Interview: Christopher Anzalone
Wall Street Transcript (Tue, Sep 15)
• ImmuneRegen BioSciences(R) Partners With University of Rochester in BARDA Funding Bid
Marketwire (Wed, Sep 9)
More Headlines for IRBS.OB...
ANALYST
EPS Est (next year) (Dec-69) : N/A
EPS Est (in 2 years) (Dec-69) : N/A
Avg Rec (current)*: 1.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
IR BioSciences Holdings, Inc., a development-stage biotechnology company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of Homspera and its derivatives, Radilex and Viprovex.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices